IEEE Launches 802.3™ Beyond 400Gb/s Ethernet Study Group to Define Next High Speed Threshold for Ethernet Data Rate
3.12.2020 18:30:00 EET | Business Wire | Press release
IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and IEEE Standards Association (IEEE SA) today announced the formation of a study group within the IEEE 802.3™ Ethernet Working Group. With bandwidth demand growing across all areas of Ethernet connectivity globally, the IEEE 802.3 Beyond 400Gb/s Ethernet Study Group will explore initiating a new IEEE project that would standardize capabilities exceeding today’s maximum data rate of 400 Gigabit per second (Gb/s) for IEEE 802.3, IEEE Standard for Ethernet.
The publicly available IEEE 802.3™ Ethernet Bandwidth Assessment (BWA) report, released in April 2020, showed that trends around traffic drivers such as video, hyperscale data centers, 5G and deployment of IEEE 802.11™ “Wi-Fi®” all point toward an ongoing bandwidth explosion for Ethernet networks around the world in the years ahead. Undeniably, simultaneous trends point toward more users, faster access speeds, more services, more devices coming online, greater difference between average and peak bandwidth demands on networks. Furthermore, the year-long study of global usage and trends that informed the IEEE 802.3 Ethernet Bandwidth Assessment report was completed before the global COVID-19 pandemic, which has only magnified the need for connectivity and bandwidth to people everywhere.
Expertise from across application spaces around the world will come together in the new study group to consider the definition of a project to define Ethernet rates beyond the current maximum rate currently defined for IEEE 802.3 Ethernet, 400 Gb/s. The first meeting of the newly launched IEEE 802.3 Beyond 400 Gb/s Ethernet Study Group is scheduled for the IEEE 802.3 Ethernet Working Group’s interim session the week of 18 January 2021.
“The path to beyond 400 Gb/s Ethernet exists, but there are a host of options and physical challenges that will need to be considered to take the next leap in speed rate for Ethernet,” said John D’Ambrosia, Distinguished Engineer, Futurewei Technologies, who led the call for interest in forming the IEEE 802.3 Beyond 400 Gb/s Ethernet Study Group. “Both the historical trend lines for Ethernet bandwidth demand and everything the industry understands today about its future needs and technology growth curves indicate that the time to take the next step is now, in order to satisfy humanity’s needs and desires for connectivity. It will be the responsibility of the study group to examine the problem and develop the project authorization documentation necessary to launch a new standard-development project.”
IEEE 802 encompasses a diverse library of standards addressing a broad array of protocols and applications. The standards developed by thousands of IEEE 802 technical experts over the past 40 years have enabled the industry to connect the world. Commencing in February 1980, IEEE 802.3 initially was developed to standardize connectivity among devices inside a local area network (LAN). The standard has steadily evolved in the decades since to deliver increased capacities and connect more users and devices across more types of networks. IEEE 802.3ba™, published in 2010, defined 40Gb/s Ethernet and 100Gb/s Ethernet; IEEE 802.3bs™, published in 2017, defined 200 Gb/s Ethernet and 400 Gb/s Ethernet. Deployment of technology defined by IEEE 802 standards is global, driven by the ever-growing needs of data networks and new application areas. New bandwidth-generating applications constantly are being introduced across mobile, video, artificial intelligence, virtual/augmented reality, etc., driving the need for higher-speed Ethernet connectivity.
Cedric Lam, principal engineer, Google, participated heavily in the consensus-building effort which led to the launch of the IEEE 802.3 Beyond 400 Gb/s Ethernet Study Group. He said, “Bandwidth demand is ever increasing, and the industry must always be building new capacity to accommodate modern demands for connectivity and the advancement of new and innovative services.”
Individuals and organizations are encouraged to learn more about IEEE 802 initiatives and get involved.
To learn more about IEEE SA or about any of its many market-driven initiatives, visit us on Facebook, follow us on Twitter, connect with us on LinkedIn or on the Beyond Standards Blog.
About the IEEE Standards Association
IEEE Standards Association (IEEE SA) is a collaborative organization where innovators raise the world's standards for technology. IEEE SA provides a globally open, consensus-building environment and platform that empowers people to work together in the development of leading-edge, market-relevant technology standards and industry solutions shaping a better, safer and sustainable world. For more information, visit https://standards.ieee.org.
About IEEE
IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at http://www.ieee.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005124/en/
Contact information
Tania Olabi-Colon, Director Marketing Communications
+1 732 562-3958, t.olabi@ieee.org
Olivia Wang, Associate Marketing Communications Manager
+1 732-562-5375, wang.x@ieee.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
